The chronic obstructive pulmonary disease (COPD) market is projected to grow at a compound annual growth rate (CAGR) of 3.7% from $9.9bn in 2015 to $14.1bn by 2025, according to a report by GlobalData.

Titled ‘PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2025’, the report covers the eight major markets of the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

The growth is attributed to key factors such as an increase in COPD cases and the launch of new bronchodilator drug classes and anti-eosinophilic biologics.

Two new bronchodilator drug classes, including combinations of beta2-agonists / long-acting muscarinic antagonists (LABA / LAMA) and inhaled corticosteroids / LABA / LAMA (ICS / LABA / LAMA) are expected to capture market share from LABA and LAMA monotherapies.

AstraZeneca and GlaxoSmithKline (GSK) are expected to emerge as major players in the market by 2025. Boehringer Ingelheim, once the market leader in 2015, lacks a first-in-class COPD late-stage pipeline product to offset the patent expiry of Spiriva HandiHaler. Boehringer Ingelhrner is, therefore, expected to garner sales of $1.6bn by 2025.

"The growth is attributed to key factors such as an increase in COPD cases and the launch of new bronchodilator drug classes and anti-eosinophilic biologics."

AstraZeneca and GSK, on the other hand, are investing heavily in new products and are expected to lead the market by 2025, opines Alexandra Annis, MS, Healthcare Analyst at GlobalData. The two companies are expected to garner sales of $3.1bn and $5.1bn respectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Despite the launch of new therapies for COPD, lack of treatments that can reverse disease progression is a significant unmet need. Treatments currently being launched in the market are aimed at preventing exacerbations with no clear data available to prove their efficacy in reducing mortality rates.

GSK’s Nucala (mepolizumab) and AstraZeneca’s benralizumab, which are in the pipeline, are the only treatments having a novel mechanism of action. These therapies are expected to be prescribed as add-on therapies for patients at high risk of exacerbations and with high levels of blood eosinophilia.

Nucala and benralizumab are expected to garner sales of $1.2bn and $817.9m respectively in the US by 2025, adds Annis.